DENVER — In 2026, the biggest drivers of market trends in ophthalmology include rare diseases as well as gene therapies and AI, according to a speaker at Eyecelerator@ARVO.
When looking at the current disease landscape, treatment areas such as glaucoma, uveitis and dry eye disease have a high number of both marketed assets and clinical assets, making them “mature indications with lots of patients, but also lots of competition,” Long Sha, PhD, of Boston Consulting Group, said during a presentation. The highest levels of mergers and acquisitions remain concentrated in the retinal disease market,